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hatever the antidepressant drug prescribed,
30%
1 to 50%
2 of adult patients with major depression fail
to respond to adequate first-line treatment,defined as a
dose in the therapeutic range given for an adequate dura-
tion,ie,4 to 6 weeks.
3 In clinical practice,when a patient
responds insufficiently to an initial antidepressant dose,
several options are available, such as temporizing,
increasing the dose,switching to another antidepressant,
or combining several drugs.
4A survey by Fredman et al
5
of attendees at a psychopharmacology course showed
that 80% or more indicated that their first choice would
be to raise the selective serotonin reuptake inhibitor
(SSRI) dose for a hypothetical patient with minimal
response after 4 weeks,or partial response after 8 weeks,
of adequate treatment,ie,fluoxetine 20 mg/day,sertra-
line 100 mg/day,or paroxetine 20 mg/day.For a patient
with no response after 8 weeks of adequate SSRI treat-
ment,a switch to a non-SSRI drug was the first and pre-
ferred strategy. Hirschfeld et al
4 advocated switching,
combination therapy, or augmentation therapy after 
4 weeks for patients who fail to respond at an adequate
dosage of SSRI (ie, <25% decrease in the Hamilton
Rating Scale for Depression [HAMD] or Montgomery
and Åsberg Depression Rating Scale [MADRS] score).
For those patients who achieve a partial response on first-
line therapy (ie, 25% to 50% decrease in HAMD or
MADRS score),they proposed that treatment should be
continued for 6 to 8 weeks at an adequate dose before
considering a change in therapeutic management.
4
An important question is whether the frequently applied
strategy of increasing the dose of antidepressant is justi-
fied.The issue is of fundamental and clinical relevance.
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Antidepressant drugs are widely recommended for the
treatment of depressive disorders, and finding the “right
dose for the right patient” is an important issue.
Whatever antidepressant is prescribed, a proportion of
adult patients with major depression fail to respond sat-
isfactorily to adequate first-line treatment. A frequent
strategy for patients with insufficient response to an ini-
tial antidepressant dose is to increase the dose. This
review is about this strategy, ie, the possible benefits of
prescribing higher doses of recent antidepressants. The
results show that a flat dose–response curve is a class
phenomenon for selective serotonin reuptake inhibitors
(SSRIs), according to randomized, controlled, fixed-dose
clinical trials. For the serotonin and noradrenaline reup-
take inhibitors (SNRIs), the strategy of dose increase may
be relevant for venlafaxine, in order to increase the
number of responders. Thus, the subgroup of patients
for whom high doses of SSRIs could be useful remains to
be defined.  
© 2005, LLS SAS Dialogues Clin Neurosci. 2005;7:249-262.Indeed,many patients receive more than the starting dose
(ie,more than one tablet of the recent antidepressant per
day) during the course of treatment.Such a prescribing
pattern implies the existence of a positive dose–response
relationship.
Three categories of dose–response studies are found in the
antidepressant literature.The first is considered to be the
best method to evaluate a dose–response relationship,and
consists of randomized,double-blind studies comparing
two or more fixed doses of antidepressants with placebo.
The second category consists of randomized,double-blind
studies comparing fixed doses of antidepressants without
placebo or with an active comparator.The third category
includes the studies of dose augmentation when the treat-
ment response is insufficient. Some, but not all, studies
include the measurement of plasma levels of antidepres-
sants.This approach enables study of response in terms of
concentration–response relationship (these concentra-
tion–response studies are not discussed here).There are
three possible shapes for the relationship between clinical
efficacy and dosage:a flat dose–response curve;a curvi-
linear dose–response curve;and a linear dose–response
curve.
6
Materials and methods
A literature search was performed for randomized con-
trolled double-blind studies comparing fixed doses of
SSRIs or serotonin and noradrenaline reuptake
inhibitors (SNRIs) with or without placebo or with an
active comparator,and studies of dose augmentation in
inadequate responders in the treatment of depressive dis-
orders,published from 1980 to 2004.Studies were classi-
fied according to the antidepressant drug used (citalo-
pram,escitalopram,fluoxetine,fluvoxamine,paroxetine,
sertraline,milnacipran,or venlafaxine),the type of the
study,and the duration of the study,ie,short-term (acute
phase) versus long-term (maintenance phase). Meta-
analyses were also selected to obtain additional infor-
mation about treatment effects.
We followed a classical method of reviewing studies,ie,
it was not based on the calculation of effect size, odds
ratio,or the number needed to treat.Efficacy measures
were analyzed using intent-to-treat (ITT) patients with
last observation carried forward (LOCF) method,and
observed cases by study visit (weekly cases analysis) or
at the end of the studies (completer cases analysis).Total
score,change of total score,or percentage of responders
on the clinical scales were considered.Visual inspection
of the figures or data in the publication concerned was
also used to appreciate the difference (or lack thereof)
between the doses of antidepressants.
We describe here those studies that are methodologically
more relevant in terms of number of patients.Studies with
a small number of patients were not included in the tables.
The studies generally followed a similar protocol. The
HAMD 21 items,
7 17 items,
8 or 24 items,the MADRS 10
items,
9 and the Clinical Global Impression Scale (CGI)
were the most widely used reference scales.Most studies
began with a single-blind placebo run-in for 1 to 2 weeks
before randomization to the double-blind phase.Efficacy
measures were total score on the rating scales,their change
from baseline,or the response rate.Responders were gen-
erally defined as patients with a decrease in the HAMD
or MADRS total score of at least 50% after at least 
3 weeks of therapy (or time not given),or a score of 1 or 2
on the CGI.
Parallel-group dose comparison studies
Citalopram
The short-term studies with citalopram did not show sig-
nificant differences in terms of clinical efficacy across a
dose range of 20 to 60 mg/day.Even a dose of 10 mg/day
was effective compared with placebo.
10The results of the
maintenance study by Montgomery et al
11 and the meta-
analysis by the same authors
12 support these findings.
Therefore, for the majority of patients, there is no
advantage of increasing the dose of citalopram above 
20 mg/day.The study by Montgomery et al
11 is particu-
larly interesting,because,in the acute double-blind phase
of one of the two initial studies (Table I),
13 citalopram 
20 mg/day was no more effective than placebo.However,
in the long-term phase,the relapse rate was similar in the
group of responders on citalopram 20 mg/day who were
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Selected abbreviations and acronyms
CGI Clinical Global Impression
HAMD Hamilton Rating Scale for Depression
ITT intent-to-treat
LOCF last observation carried forward
MADRS Montgomery and Åsberg Depression Rating
Scale
SNRI serotonin and noradrenaline reuptake inhibitor
SSRI selective serotonin reuptake inhibitorrandomized to placebo and in the group of those who
were responders and continued in double-blind on
placebo,but higher than in the group of those who were
randomized to continue on citalopram 20 mg/day.These
results tend to show that citalopram 20 mg/day was effec-
tive in the acute phase despite the observation that it was
not significantly different from placebo.
The study by Montgomery et al
13 failed to show a bene-
fit of citalopram 20 mg/day on the HAMD 17 items and
MADRS total scores in a group of 56 evaluable patients,
ie,those who remained at least 3 weeks in the study;only
citalopram 40 mg/day,in a group of 49 evaluable patients,
was superior to placebo and to citalopram 20 mg/day.
When using change on the HAMD and MADRS total
score, citalopram 20 and 40 mg/day were no different
from placebo.Using the 50% reduction on the HAMD
and MADRS total score, there were no differences
between citalopram 20 and 40 mg/day and placebo at the
end of 6 weeks. In other words, there were no more
responders in the two citalopram groups than in the
placebo group.All analyses were carried out on a LOCF.
In a large study by Feighner and Overo (Table I),
14 citalo-
pram 40 and 60 mg/day,but not 10 and 20 mg/day,were
more effective than placebo on change on the HAMD 21
items total score on ITT-LOCF at the end of 6 weeks.
However,there was no statistical analysis comparing the
different doses of citalopram.The percentage of respon-
ders on the MADRS on LOCF was significantly higher
in each group of citalopram dose compared with placebo;
there was no statistical analysis comparing the different
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Table I. Selective and serotonin reuptake inhibitors (SSRIs) and dose–efficacy relationship in parallel-group dose comparison studies ranked in order of
increased efficacy. HAMD, Hamilton Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale; ITT, intent-to-treat;
LOCF, last observation carried forward; NA, not applicable; =, efficacy similar to; <, efficacy inferior to.
Drug No of patients in  Dose  Total duration  LOCF analysis Completer cases analysis
double-blind phase escalation (weeks)
Citalopram
13 n=199 1 week 6 Placebo = 20 mg/day < 40 mg/day NA
Evaluable patients=155 (total score HAMD and MADRS)
Placebo = 20 mg/day = 40 mg/day
(change from baseline)
Citalopram
14 n=650 1 week 6 Placebo = 10 mg/day = 20 mg/day NA
ITT=650 < 40 mg/day = 60 mg/day
(change from baseline HAMD)
Escitalopram
15 n=491 1 week 8 Placebo < 10 mg/day = 20 mg/day Placebo < 10 mg/day = 20 mg/day
ITT=485 = 40 mg/day citalopram = 40 mg/day citalopram
Completers=373 (change from baseline HAMD  (change from baseline HAMD 
and MADRS) and MADRS)
Fluoxetine
16 n=356 No 6 Placebo = 60 mg/day  Placebo < 20 mg/day = 40 mg/day
ITT=345 < 20 mg/day = 40 mg/day = 60 mg/day
(change from baseline HAMD) (change from baseline HAMD)
Fluoxetine
17 n=363 No 6 Placebo < 5 mg/day  Placebo < 5 mg/day = 20 mg/day
ITT=354 = 20 mg/day = 40 mg/day = 40 mg/day
(change from baseline HAMD) (change from baseline HAMD)
Fluvoxamine
18 n=600 2 weeks 8 Placebo = 25 mg/day = 50 mg/day  NA
ITT=577 = 150 mg/day < 100 mg/day
(total score HAMD13)
Paroxetine
19 n=460 No 6 Placebo = 10 mg/day < 20 mg/day  NA
ITT=454 = 30 mg/day = 40 mg/day
(change from baseline HAMD)
Sertraline
20 n=369 No 6 Placebo < 50 mg/day =100 mg/day  Placebo < 50 mg/day =100 mg/day
ITT=347 = 200 mg/day = 200 mg/day
Evaluable patients=289 (change from baseline HAMD) (change from baseline HAMD)
Completers=191doses of citalopram between them,but visual inspection
of the figures in the publication
14 suggests no such differ-
ence. Bech et al
10 reexamined this study using another
psychometric approach,ie,the depression core subscales
of the HAMD (HAMD6) and MADRS (MADRS6) in
particular.Antidepressive and antianxiety effects could
be observed after 6 weeks of therapy even at a dose of
citalopram 10 mg/day,and these effects were found to be
significantly superior to placebo.Both citalopram 10 and
20 mg/day had lower effect sizes (around 0.30 on the sub-
scales and 0.20 on the scales) than 40 and 60 mg/day
(around 0.54 on the subscales and 0.40 on the scales) at
6 weeks.However,the confidence intervals indicated that
there were no statistically significant differences:all doses
were superior to placebo,but 40 and 60 mg/day were not
significantly superior to 10 or 20 mg/day.
In a small study by Bjerkenstedt et al
21 (not included in
Table I) with 8 to 10 patients in each of 3 groups,there
were no differences between citalopram 5, 25, and 50
mg/day at the end of 4 weeks on the global rating of men-
tal health (sum of the MADRS ratings and Beck self-rat-
ings scale for depression).Even at the lowest dose,there
was a significant reduction in depressive symptoms in
comparison with baseline.
The maintenance study by Montgomery et al
11 included
patients of two double-blind,placebo-controlled,6-week
acute trials; one of these was published by the same
authors in 1992.
13 There were no differences between
citalopram 20 and 40 mg/day at the end of 24 weeks;both
doses were equally effective,as measured by both relapse
rates and time to relapse.The relapse rate among the 48
patients who continued to receive citalopram 20 mg/day
(8%) and the 57 patients who continued to receive citalo-
pram 40 mg/day (12%) was significantly lower than that
in the 42 patients randomized to placebo (31%).
In a meta-analysis of 9 placebo-controlled studies by
Montgomery et al,
12 2 fixed-dose studies (474 patients)
and 7 flexible-dose studies were included for a total of
949 patients,586 of whom received citalopram and 363
placebo. Only patients who were treated for at least 
4 weeks were included in the meta-analyses.For change
in HAMD total score,available data showed that citalo-
pram 20 mg/day (n=61) and 40 mg/day (n=74),but not 
60 mg/day (n=38),were superior to placebo (n=154);the
two lowest dosages were similarly effective on visual
inspection of the figures in the publication.
12 For change
in the MADRS total score,available data showed that
citalopram 20 mg/day (n=123) and 40 mg/day (n=136)
were superior to placebo (n=140); the two citalopram
dosages were similarly effective on visual inspection of
the figures in the publication.
12 The authors concluded
the similarity of efficacy—or flat dose–response curve—
of citalopram 20,40,and 60 mg/day doses.
Escitalopram
The only fixed-dose–response study with escitalopram
indicates that 10 mg/day was equally as effective as 
20 mg/day (Table I).
15 Patients with more severe depres-
sion might respond better with doses of escitalopram
above 10 mg/day.
22
In the study by Burke et al,
15 escitalopram 10 and 
20 mg/day and the racemic form citalopram 40 mg/day
were more effective than placebo on change on the
HAMD 24 items and MADRS total score at the end of 8
weeks.There was no statistical analysis between the two
doses of escitalopram,but visual inspection of the figures
in the publication
15 does not suggest such a difference.
Differences in response rate between each of the esci-
talopram dosage groups (50% and 51.2% for 10 and 
20 mg/day,respectively) and the racemic form citalopram
group (45.6%) were not significant,but the response rates
were significantly greater for each group of active sub-
stance compared with the 27.7% response on placebo,
with LOCF analysis in the MADRS.According to Bech et
al,
22 who reexamine this study using another psychometric
approach,
10 when all included patients were analyzed,no
dose–response relationship was seen.However,in the 212
severely depressed patients (MADRS total score ≥30),a
positive dose–response relationship for escitalopram was
seen on MADRS and the two subscales (HAMD6,
MADRS6) after 6 and 8 weeks of therapy.At the end of 
8 weeks, the effects sizes, analyzed on ITT-LOCF, were
around 0.34 on the subscales and 0.32 on MADRS for esci-
talopram 10 mg/day,around 0.73 on the subscales and 0.71
on MADRS for escitalopram 20 mg/day,and around 0.46
on the subscales and 0.37 on MADRS for racemic form of
citalopram 40 mg/day.Only escitalopram 20 mg/day and
the racemic form of citalopram 40 mg/day were superior
to placebo.However,the confidence intervals indicated
that the differences were not significant.
Fluoxetine
The studies with fluoxetine did not show significant dif-
ferences in terms of clinical efficacy across a dose range
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252of 20 to 60 mg/day.Even a dose of 5 mg/day was effective
compared with placebo (Table I).
17 Therefore, for the
majority of patients,there is no advantage of increasing
the dose of fluoxetine above 20 mg/day.It might even be
the case that the higher dose of 60 mg/day is less effec-
tive in major depressive disorder.
23
In the first study by Wernicke et al (Table I),
20 doses of flu-
oxetine 20 and 40 mg/day,but not 60 mg/day,were more
effective than placebo on change on the HAMD total
score on ITT-LOCF at the end of 6 weeks.Fluoxetine 20
and 40 mg/day were statistically superior to 60 mg/day.No
statistical comparison was performed between fluoxetine
20 and 40 mg/day,but visual inspection of the data in the
publication
16 suggests that there was no such difference.
The higher number of discontinuations in the 60-mg/day
group, in particular because of side effects, might have
skewed the results,with only 45% patients who completed
in the higher dosage group compared with 62% and 60%
in the 20- and 40-mg/day groups,respectively.The weekly
analysis with patients who remained in the study showed
more efficacy for the three doses of fluoxetine compared
with placebo on change on the HAMD total score at the
end of 6 weeks.No statistical comparison was published
between the active treatment groups but visual inspection
of the figures in the publication
16 does not suggest such dif-
ferences.The response rates in patients treated for at least
3 weeks were 52.8%,60.6%,and 48.4% on fluoxetine 20,
40,and 60 mg/day,respectively,and significantly different
for each group of active substance from the 27.3%
response on placebo on the HAMD.
In a second study by Wernicke et al
17 in a different patient
population (Table I),fluoxetine 5,20,and 40 mg/day were
more effective than placebo on change on the HAMD
total score on ITT-LOCF at the end of 6 weeks.No statis-
tical comparison was made between fluoxetine 5,20,and
40 mg/day,but visual inspection of the data in the publi-
cation
17 suggest that there was no difference.The weekly
analysis with patients who remained in the study showed
more efficacy for the 3 doses of fluoxetine compared with
placebo on change on the HAMD total score at the end
of 6 weeks.No statistical comparison was shown between
the active treatment groups but visual inspection of the fig-
ures in the publication
17 did not suggest any differences.
The response rates in patients treated for at least 3 weeks
were 54.4%,64.3%,and 64.7% on 5,20,and 40 mg/day,
respectively, which were significantly different for each
group with active treatment from the 32.7% response on
placebo on the HAMD.
Beasley et al
23 pooled the data from the two studies by
Wernicke et al.
16,17They found that the efficacy of fluox-
etine 60 mg/day did not differ from placebo, and that
there were no significant differences among the doses of
5,20,and 40 mg/day on change on the HAMD total score
on ITT-LOCF.Response rate (49.4% for 5 mg/day and
54% for 20 mg/day) and remission rate defined as
HAMD total score decreased to 10 or less after at least
3 weeks (40.2% for 5 mg/day and 43.5% for 20 mg/day)
showed a similar pattern.The authors concluded that flu-
oxetine 5 mg/day might be a threshold dose for thera-
peutic efficacy.
The study by Fabre and Putman
24 (not included in Table
I) included patients with different degrees of depression.
In the 38 patients with mild illness (HAMD of 14 to 19),
with 20 who completed the study,there was no significant
improvement at any of the fluoxetine dose level of 20,40,
or 60 mg/day compared with placebo at the end of 6
weeks. In the 46 patients with moderate-to-severe
depression (HAMD of ≥20),with 27 who completed the
study,change in the HAMD total score was not signifi-
cantly different between active treatment groups,but was
significantly different for the placebo group compared
with all fluoxetine dose groups,except for the 40-mg/day
group.
Dunlop et al
25 have studied 372 patients with mild
depression (HAMD of 15 to 19) (not included in Table
I). Fluoxetine 20, 40, and 60 mg/day each produced an
improvement that was no different from placebo on
change in the HAMD total score in 355 ITT patients
with LOCF at the end of 6 weeks.The results with com-
pleter cases analysis, ie, 214 patients who finished the
study,on change in the HAMD total score were similar
to those of the ITT-LOCF analysis.The response rates in
HAMD total score for 260 patients treated at least 3
weeks were 53%,51%,and 59% on fluoxetine 20,40,and
60 mg/day,respectively,and were significantly different
from the 36% response on placebo only for fluoxetine 60
mg/day.Persistent improvement and delayed persistent
improvement were significantly more frequent in each
active treatment group than in the placebo group on the
CGI scale,according to a pattern analysis that permitted
to evaluate true drug response to antidepressants,char-
acterized both by 2 weeks or greater delay in onset of ini-
tial improvement and nonfluctuating persistence of it
once achieved
26,27;there were no differences between the
three fluoxetine groups on visual inspection of the figures
in the publication.
25
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Fluvoxamine
The only fixed-dose–response study of fluvoxamine has
two characteristics (Table I).
18 First,it included a low dose
of 25 mg/day fluvoxamine.Second,in the primary effi-
cacy assessment,the authors excluded 8 items from the
HAMD 21 items,such as insomnia,agitation,psychic and
somatic anxiety,gastrointestinal symptoms,and general
somatic symptoms,which are common to depression and
SSRI side effects.This exclusion is unusual because all
SSRIs have these clinical manifestations as potential side
effects (other studies did not delete these items).A grad-
ual escalation was performed over 2 weeks and the
authors considered only the final 6 weeks at fixed dose
in the evaluation of efficacy.When the HAMD 21 items
total score was used, no significant treatment effects,
compared with placebo, were noted at the end of the
study.
In this fixed-dose study on a large sample,
18 only fluvox-
amine 100 mg/day showed a significant therapeutic ben-
efit over placebo at end-point analysis (on LOCF) on
modified HAMD 13 items final score at the end of 6
weeks at fixed dose.Significant differences were not seen
between fluvoxamine 25,50,or 150 mg/day or placebo.
On the HAMD 13 items responder analysis,the differ-
ences were significant for fluvoxamine 100 and 150
mg/day compared with placebo,but not between these
two dosages on visual inspection of the figures in the
publication
18 on completer cases analysis.
Paroxetine
In the publication by Dunner and Dunbar (Table I),
19
there is a short description of a study involving 460
patients.The paroxetine 10 mg/day dose was no more
effective than placebo, even on the HAMD depressed
mood item.The authors reported also on a pooled analy-
sis from a worldwide database,involving 1091 patients
who remained on a fixed dose of paroxetine or placebo
for at least 4 weeks,which showed no differences in terms
of clinical efficacy across a dose range of 20 to 40 mg/day
paroxetine.Therefore,for the majority of patients,there
is no advantage in increasing the dose of paroxetine
above 20 mg/day.
In this study,
19 there were no differences between
paroxetine 10 mg/day and placebo on change on the
HAMD total score at the end of 6 weeks. Significant
differences were seen between other doses of paroxe-
tine of 20, 30, and 40 mg/day and placebo.There were
no differences between the three higher dosages of
paroxetine on visual inspection of the figures of the
publication.
19
Sertraline
The SSRI sertraline did not show significant differences
in terms of clinical efficacy across a dose range of 50 to
200 mg/day, according to a major study by Fabre and
Putman  (Table I).
20 Therefore, for the majority of
patients,there is no advantage to increase the dose of ser-
traline above 50 mg/day.
In the study by Fabre and Putman,
20 sertraline 
50 mg/day,but not 100 and 200 mg/day,was more effec-
tive than placebo at end-point analysis on change on the
HAMD 17 items total score on ITT-LOCF at 6 weeks.
There was no statistical analysis performed between the
different doses, but inspection of the data in the publi-
cation
20 suggests no differences. Evaluable patients,
defined as those who had taken study medication at
least up to the 11th day of the double-blind phase,with
efficacy assessment performed on or after this date.
With this population of 289 evaluable patients,all doses
of sertraline were statistically superior to placebo on
change on the HAMD total score with LOCF at the
end of 6 weeks.There was no statistical analysis of the
different doses, but inspection of the data in the publi-
cation
20 suggests no differences; on the CGI, the per-
centage of responders was 58.5%, 62.7%, 58.9%, and
42.1% in the sertraline 50,100,200 mg/day and placebo
groups, respectively. Inspection of the data in the pub-
lication
20 for the 191 patients who completed the study
suggests no difference between the three doses of 
sertraline on change on the MADRS total score.
Moreover, efficacy was similar in patients with moder-
ate depression (HAMD score at baseline:17 to 24) and
with severe depression (HAMD score at baseline:25 or
more).A small part of this study with 30 patients had
been released 6 years earlier in a short publication,
28
with the same conclusions.
In a very small study in 17 patients at the start of the
study and 8 at the end,Guy et al
29 could not demonstrate
the efficacy of sertraline 50 and 100 mg/day over placebo
on the HAMD 17 items at the end of 4 weeks.No symp-
tomatic improvement was noted for sertraline 200 or 400
mg/day.Lower dosages were better tolerated than higher
dosages.Dose–response relationship for recent antidepressants - Berney Dialogues in Clinical Neuroscience - Vol 7 . No.3 . 2005
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Milnacipran
Three fixed-dose studies
30-32 and one dose-ranging study
33
were identified for milnacipran (Table II).The studies
showed flat dose–response relationship between 100 and
300 mg/day; milnacipran 50 mg/day was less effective
than higher doses and even than placebo.
In a study by Ansseau et al,
30 milnacipran was prescribed
at a dose of 50 or 100 mg/day,with a third group receiv-
ing amitriptyline 150 mg/day.At the end of 4 weeks at
fixed doses,milnacipran 100 mg/day was as effective as
amitriptyline 150 mg/day on change in mean scores on
the HAMD 24 items and MADRS with time,in the 109
patients who were treated for the whole period (com-
pleter cases).The authors concluded that milnacipran 100
mg/day was more effective than 50 mg/day,but statistical
analysis was not in favor of this conclusion.
In a dose-ranging study by Ansseau et al,
33 the dose–response
at fixed doses could only be evaluated for the first 2 weeks.
On visual inspection of the figures in the publication,
33 there
were no differences between milnacipran 200 and 300
mg/day and fluvoxamine 200 mg/day on change in mean
scores on the HAMD 24 items and MADRS with time.
Lecrubier et al
31 described a study with three dosages of
milnacipran 50, 100, and 200 mg/day. At the end of 
8 weeks, in a total of 412 patients, milnacipran 100
mg/day, but not 50 or 200 mg/day, was more effective
than placebo on change on the HAMD 17 items total
score; milnacipran 100 and 200 mg/day, but not 50
mg/day,was superior to placebo on change in MADRS
total score.There was no statistical analysis between the
three doses of milnacipran,but inspection of data in the
publication
31 suggests that milnacipran 100 and 200
mg/day were superior to 50 mg/day,and that there was
no difference between them.The percentage of respon-
ders,for a total of 412 patients,were 48%,65%,and 53%
in milnacipran 50-,100-,and 200-mg/day groups,respec-
tively, compared with 44% in placebo group on the
HAMD;the difference was only significant between mil-
nacipran 100 mg/day and placebo.
In the study by Guelfi et al,
32 milnacipran was prescribed
at doses of 100 and 200 mg/day,with a third group receiv-
ing fluoxetine 20 mg/day.At the end of 12 weeks,there
were no differences between the three groups on change
on the HAMD 17 items and MADRS total scores on
ITT-LOCF. Per protocol analysis, ie, 237 patients who
Table II. Milnacipran and dose–efficacy relationship in parallel-group dose comparison studies ranked in order of increased efficacy. HAMD, Hamilton
Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale; ITT, intent-to-treat; LOCF, last observation carried for-
ward; NA, not applicable; =, efficacy similar to; <, efficacy inferior to.
Reference No patients Dose Total Control LOCF analysis Completer cases analysis
in double-blind escalation duration group
phase (weeks)
Ansseau et al,
30 n=144 5 days 4-7 Amitriptyline 50 mg/day < 100 mg/day 50 mg/day < 100 mg/day
1989 Included in  150 mg/day = 150 mg/day = 150 mg/day
analysis=131 (change over time
Completers=109  HAMD and MADRS)
Ansseau et al,
33 n=127 No 4 Fluvoxamine 7 dropouts in first 2 weeks 200 mg/day = 300 mg/day 
1991 Included in  200 mg/day = 200 mg/day
analysis=120 first 2 weeks
(change over time 
HAMD and MADRS)
Lecrubier et al,
31 n=527 NA 8 Placebo NA Placebo = 50 mg/day < 100 mg/day
1996 Included in  = 200 mg/day
analysis=412  (change from baseline 
HAMD and MADRS)
Guelfi et al,
32 n=300 No 12 Fluoxetine 100 mg/day = 200 mg/day NA
1998 ITT=289 20 mg/day = 20 mg/day
(change from baseline 
HAMD and MADRS)completed at least a 14-day treatment period,showed  no
differences between the three groups on change on the
HAMD and MADRS total scores at the end of 12 weeks.
The responders rate were 62%, 54%, and 51% on
HAMD, and 64%, 55%, and 49% on MADRS in mil-
nacipran 100 and 200 mg/day,and fluoxetine 20 mg/day
groups, respectively on ITT-LOCF; the difference was
only significant between milnacipran 100 mg/day and flu-
oxetine 20 mg/day on the MADRS.
Venlafaxine
In the venlafaxine studies, doses varied between 25 and 
375 mg/day (Table III).A positive dose–response curve was
only demonstrated with trend analysis.However,the dif-
ference between the higher dose range and placebo was not
pronounced.
34 Better efficacy could be obtained with a dose
of venlafaxine above 75 mg/day in terms of remission rate.
36
In a review concerning all aspects of antidepressant use,
Preskorn
2 mentioned an ascending then descending
dose–response curve for venlafaxine in an evaluation
comparing 7 dose levels between 25 and 375 mg/day with
placebo, coming from fixed- and flexible-dose studies.
However,the major difference in terms of mean HAMD
score change,ie,2 points,was between a group of patients
receiving 175 mg/day and another receiving 182 mg/day,
hardly a different dose! This suggests a calculation arti-
fact rather than a pharmacological dose–response curve.
2
For the majority of patients, a dose of venlafaxine 75
mg/day should be adequate.
In a study by Mendels et al,
34 venlafaxine was prescribed
at fixed dose of 25 mg/day for the low-dose group and at
fixed interval dose of 50 to 75 mg/day and 150 to 
200 mg/day for 2 other groups,with a fourth group receiv-
ing placebo. At the end of 6 weeks, there was a high
placebo response and only trend analysis on ITT-LOCF
was statistically significant and showed that efficacy
improved with increasing doses of venlafaxine according
to change in the HAMD 21 items and MADRS. The
results for completer cases analysis were not interpretable.
Kelsey et al
37 analyzed other aspects of the above study
34
and found a significant difference in response rate
between the high-dose group and the placebo group on
the basis of the HAMD and MADRS total scores;none
of these data were described numerically in the article.
In the study by Khan et al,
35 venlafaxine was prescribed
at fixed doses of 75,150,and 200 mg/day.At the end of
12 weeks,among the 353 or 346 ITT patients (the authors
are imprecise on this issue),each dose of venlafaxine was
significantly superior to placebo on the HAMD 21 items
total score with LOCF.For the MADRS total score,the
authors reported that each dose of venlafaxine was also
significantly superior to placebo (data not shown in the
publication). No statistical analysis was performed
between each group of active treatment, but visual
inspection of the data in the publication
35 on the HAMD
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Table III. Venlafaxine and dose–efficacy relationship* in parallel-group dose comparison studies ranked in order of increased efficacy. HAMD, Hamilton
Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale; ITT, intent-to-treat; LOCF, last observation carried for-
ward; NA, not applicable; =, efficacy similar to; <, efficacy inferior to.
Reference No patients Dose Total LOCF analysis Completer cases analysis
in double-blind escalation duration
phase (weeks) (weeks)
Mendels et al,
34 n=312 1 6 Placebo < 25 mg/day < 50-75 mg/day Not interpretable
1993 ITT=302 < 150-200 mg/day (change from baseline 
Completers: 232  HAMD and MADRS on trend analysis)
Khan et al,
35 n=403 1 12 Placebo < 75 mg/day = 150 mg/day  Placebo < 75 mg/day 
1998 ITT=353 or 346 = 200 mg/day = 150 mg/day
Completers=NA (total score HAMD) = 200 mg/day
Rudolph et al,
36 n=358 1 6 Placebo < 75 mg/day = 150-225 mg/day Placebo < 75 mg/day
1998 ITT=323 = 300-375 mg/day = 150-225 mg/day
Completers= (total score HAMD) = 300-375 mg/day
194 or 173  Placebo < 75 mg/day < 300-375 mg/day (total score HAMD)
=150-225 mg/day 
(change from baseline MADRS)total score with ITT-LOCF suggests no differences.
Observed cases analysis, defined as analyses of observed
patients at each time point, gave similar results.
35 The per-
centage of responders on the CGI was better for each ven-
lafaxine group, but no difference was found between the
three doses on visual inspection of the figures in the publica-
tion
35 at the end of 12 weeks with ITT-LOCF.The authors
stated that there were no significant differences in the inci-
dence of side effects between the different dosage groups of
venlafaxine.
35Among the treatment-emergent study events
that led to discontinuation from the study,there was no pos-
itive dose–response for somnolence,dizziness,asthenia,and
insomnia,while there was for nausea with 17% of patients on
higher dose and 8% on the lower dose of venlafaxine report-
ing nausea,versus 1% (a low value) in those on placebo.
In the study by Rudolph et al,
36 venlafaxine was prescribed
at fixed dose of 75 mg/day for the low-dose group and at
fixed interval dosage of 150 to 225 mg/day and 300 to 
375 mg/day for other 2 groups,with a fourth group receiv-
ing placebo.At the end of 6 weeks,significant differences
were seen between each group of active substance and
placebo on the HAMD 21 items total score with ITT-
LOCF.There were no differences between each group of
active treatment.At the end of 6 weeks, each group of
active treatment was superior to placebo,and venlafaxine
300 to 375 mg/day was superior to venlafaxine 75 mg/day,
on change on the MADRS total score on ITT-LOCF.
Among the 194 or 173 patients (the authors are imprecise
on this issue) who completed the study (completer cases),
each group of active treatment was better than placebo on
the HAMD total score.There were no significant differ-
ences between each group of active treatment.Among the
completer cases,the percentage of those who achieved a
score of 8 or less on HAMD total score was 19% on
placebo,and 25%,48%,and 54% on venlafaxine 75 mg/day,
150 to 225 mg/day,and 300 to 375 mg/day,respectively,at
the end of 6 weeks.There was no positive dose–response
for anorexia,dizziness,headache,and insomnia,while there
was one for nausea present in 58% of patients on higher
dose of venlafaxine versus 14% in those on placebo.Part of
this study has been reported previously.
38,39
Reboxetine
In most protocols, there was a gradual escalation from 
2 to 10 mg/day.For example,reboxetine 8 to 10 mg/day was
compared with imipramine 150 to 200 mg/day.
40 Thus,
despite availability of several short clinical trials,we cannot
comment on the dose–response relationship for reboxetine.
Duloxetine is not discussed here,but no positive dose–response
relationship has been found for 40 to 120 mg/day.
Dose augmentation studies in nonresponders
The three studies of dose augmentation in nonresponders
or inadequate responders were double-blind,randomized,
controlled trials with a fixed-dose design,and were all con-
ducted in outpatients (Table II).The definition of nonre-
sponders was identical in two of the studies,
41,42 but differ-
ent in the third.
43Another difference was the initial period
of the studies,where antidepressants were prescribed for
3 weeks each,but in an open,single-blind,or double-blind
manner.Finally,for the two studies with fluoxetine,a dose
augmentation was made well before the steady state was
achieved,in particular for norfluoxetine,owing to the very
long half-life of this active metabolite.
Fluoxetine
The study by Dornseif et al
41 was performed more than
15 years ago.It is of great importance because it demon-
strated that there is no advantage of tripling the dose of
fluoxetine to 60 mg/day in outpatients who fail to initially
respond to 20 mg/day for 3 weeks; during the next 5
weeks, patients in both groups responded to the same
extent and at the same rate.The response rates to fluox-
etine 20 and 60 mg/day were 40.5% and 44.7%,respec-
tively.The remission rates (HAMD 21 items ≤7) were
33.3% and 36.2%,respectively,at the end of 8 weeks.
The values of plasma levels from this study were reported
by Beasley et al.
23At the end of 8 weeks,there was no rela-
tionship with the percentage change in the HAMD total
score,in either the 20-mg/day or the 60-mg/day group.
Another dose-augmentation study was performed by
Schweizer et al
42 using a similar design to that of Dornseif
et al.
41There was no advantage in tripling the dose of flu-
oxetine to 60 mg/day in patients who had failed to
respond initially to 20 mg/day for 3 weeks.At the end of
8 weeks,49% and 50% of patients had responded to flu-
oxetine 20 and 60 mg/day,respectively.
Paroxetine
The study by Benkert et al
43 used the same protocol as
Dornseif et al
41 and Schweizer et al,
42 and evaluated two
antidepressants,paroxetine and maprotiline.This study
Dose–response relationship for recent antidepressants - Berney Dialogues in Clinical Neuroscience - Vol 7 . No.3 . 2005
257could not demonstrate an advantage of doubling the
dose of paroxetine to 40 mg/day in patients who had
failed to respond initially to 20 mg/day for 3 weeks. In
another group of 273 patients (not included in Table IV),
no advantage of increasing the dosage of maprotiline to
150 mg/day in patients who had failed to respond initially
to 100 mg/day for 3 weeks could be demonstrated. No
significant benefits of dose escalation were found.
The study by Benkert et al
43 enabled the evaluation of
the role of initial severity of depression in both groups of
patients treated with paroxetine or maprotiline.When a
separate analysis was made for minor and major depres-
sion at baseline,no significant differences were seen in
terms of efficacy between these clinically defined cate-
gories and the doses of the two antidepressants.
Discussion
Increasing the dose of antidepressants seems to be the
preferred strategy of doctors when depressed patients
have an insufficient response after 4 to 8 weeks of ade-
quate treatment.
5 However, there are surprisingly few
randomized controlled trials addressing the issue of
whether a higher proportion of patients respond when
higher doses are given.
Our review of eight clinical trials at fixed doses that have
evaluated the dose–response relationship of SSRIs in the
treatment of major depressive disorders suggests that the
dose–response curve is flat (Table I). Moreover, three
augmentation studies could not demonstrate an advan-
tage of doubling the dose of paroxetine,or tripling the
dose of fluoxetine,in patients who had failed to respond
initially to 20 mg/day for 3 weeks (Table IV).There was
a heterogeneity of the results in that some studies did not
show a significant difference between the active sub-
stance and placebo
13,18 or between the highest dosage and
placebo.
16 In other studies,doses below the lowest rec-
ommended ones were as effective as higher doses and
superior to placebo,for example,5 mg/day fluoxetine.
17
The lack of positive dose–response relationship with
SSRIs was observed in these eight trials,which were all
performed with protocols of the type that is mandatory
for the registration of a new antidepressant.The main
objective of these clinical trials was to establish efficacy,
while protocols on dose–response relationship are not
mandatory,despite the fact that some information on this
issue is mentioned in the prescription guidelines and
patient information leaflet.
Baker et al
44 have a different opinion regarding the
dose–response curve of SSRIs.They adequately under-
lined that most dose–response studies expressed a com-
posite result mixing a dose–response for beneficial effects
and another one for side effects.With their approach,ie,
excluding dropouts,they found a small increase in effi-
cacy with higher doses of SSRIs.By grouping the fixed-
doses studies of Wernicke et al
16,17 and Fabre and
Putman,
20 the slope of improvement,as evaluated from
response rates,was statistically significant on meta-analy-
sis, ie, 3.1% improvement for each 100 mg/day SSRIs
equivalents;this slope was not statistically significant for
the individual studies.Thus,Baker et al
44 concluded that
“study designs better tailored to address the relevant
clinical question would test hypotheses more appropri-
ately than previous studies.”Despite the fact that we did
not use the technique of meta-analysis in our review,we
propose that the risk of type 2 error concerning a posi-
tive dose–response relationship with SSRIs is small.
There are several methodological points to discuss in
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Table IV. Selective serontonin reuptake inhibitors (SSRIs) and dose–efficacy relationship in dose-augmentation studies in nonresponders ranked in order
of increased efficacy. HAMD, Hamilton Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale; ITT, intent-to-
treat; LOCF, last observation carried forward; NA, not applicable; =, efficacy similar to; <, efficacy inferior to.
Drug No patients First No patients Total LOCF analysis Completer cases analysis
in first period period at aug- duration
(weeks) mentation (weeks)
Fluoxetine
41 572 3 n=371 8 20 mg/day = 60 mg/day 20 mg/day = 60 mg/day
Single-blind Completers=278 (change from baseline HAMD) (change from baseline HAMD)
Fluoxetine
42 108 3 n=77 8 20 mg/day = 60 mg/day 20 mg/day = 60 mg/day
Open Completers=NA (total score HAMD) (total score HAMD)
Paroxetine
43 271 3 n=86 6 20 mg/day = 40 mg/day 20 mg/day = 40 mg/day
Double-blind Completers=NA (total score and change from  (total score and change from
baseline HAMD and MADRS) baseline HAMD and MADRS)view of the above findings.One concerns the difference
between ITT and completer cases analyses.The clinical
efficacy of antidepressants estimated according to ITT
sample does not favor active treatment. Indeed, com-
pleter cases analysis often leads to a higher rate of
improvement than ITT analysis.This might be attributed
to an increased number of dropouts as the dose of anti-
depressant is increased,as shown by Bollini et al,
45 who
considered all classes of antidepressants.From a regula-
tory point of view,the ITT analysis is important to pro-
tect the patients from a false,favorable evaluation of ben-
eficial effects of drugs. Therefore, with ITT sample
evaluation,one could expect a flat dose–response curve.
However,completer cases analyses were generally not
different from ITT analyses in these SSRI trials. This
means that higher doses of SSRIs are really no more
effective than lower doses.
A second methodological point is the proposal that
SNRIs might have a clinical superiority over SSRIs
because of the simultaneous inhibition of noradrenaline
(NA) and serotonin (5-HT) reuptake (ie,a “dual”mech-
anism).For venlafaxine,5-HT and NA reuptake inhibi-
tion were demonstrated to be sequentially engaged
according to the dose.
46 The four clinical trials at fixed
doses that have evaluated the dose–response relationship
of milnacipran in the treatment of major depression sug-
gests that the dose–response curve is flat (Table II).There
were no placebo groups in three of these studies,and the
results are not sufficiently informative in this context.
47
The three clinical trials at fixed doses that have evaluated
the dose–response relationship of venlafaxine in the
treatment of major depressive disorders showed equivo-
cal results.A significant positive trend was demonstrated
with increasing dose of venlafaxine,
34 even if some dif-
ferences between groups with low and high doses were
not significant.A higher remission rate might be achieved
with doses higher than 75 mg/day.
36
A third methodological point concerns the quality of the
trials.Most of the trials that we reviewed did not satisfy
for the Consolidated Standards of Reporting Trials
(CONSORT) statement,
48 insisting on the definition of
ITT and the reporting of a flow diagram.This applies
even though the studies were published after this docu-
ment appeared for the first time.
49 ITT patients were gen-
erally defined as all patients who took at least one dose
of medication in a double-blind condition and had at
least one postbaseline efficacy assessment either during
drug therapy or within 3 days of the last dose.These cri-
teria do not correspond to the definition of ITT patients,
ie, number of patients included in each intervention
group at the inclusion in the double-blind phase and con-
sidered in the primary data analysis.In a proportion of
studies, the flow diagram, when given, did not provide
good enough information on the number of patients who
entered each phase of the trial.
The studies used a variety of inclusion and diagnostic cri-
teria. The majority of studies with SSRIs and SNRIs
included only outpatients,but sometimes inpatients,out-
patients,and daypatients were included.
13 Minimum inclu-
sion scores on the scales were variable,which means that
initial severity of depression was not the same.Severity of
depression may influence the relationship between SSRI
or SNRI dose and clinical response.The number of previ-
ous episodes and the number of patients who had not
received antidepressants before or who had failed to
respond to one or several trials could also influence the
results.
50,51This lack of homogeneity may have obscured a
significant relationship. One possibility would be that a
better efficacy with higher doses of SSRIs exists only for
severe depression and/or for different types of depression.
In studies with flexible dosage, an apparent lack of
response early in treatment triggers an increase in dose,
sometimes up to the maximum tolerated dose,and the
response seen later is then attributed to the higher dose
rather than being identified as a possible delayed
response to a lower dose.Therefore,the efficacy is tested
at rather high doses,which,in the case of SSRIs partic-
ularly,may not be necessary.This method encourages the
clinicians to use the maximum tolerated dose rather than
the minimal effective dose.
In studies with fixed-dose design,higher doses are started
abruptly,most often without gradual escalation,or with
a short titration time, unlike in clinical practice.Thus,
early discontinuation could be expected because there
may be more side effects in the higher dosage group.For
those dropouts, the possibility of good subsequent
response cannot be excluded.This can lead to a discrep-
ancy between the results for the ITT and completer cases
analyses.In addition,the clinical response to antidepres-
sants is not observed immediately.In some patients,more
than 3 weeks are required before an improvement in
symptoms becomes obvious, while side effects appear
soon after starting treatment.
A final point is that,in clinical trials,patients represent a
carefully selected cohort in order to ensure comparable
baseline populations.In clinical practice,patients often
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and are likely to receive more complex drug regimens.
Determination of response is highly individual and does
not necessarily correspond to that performed under con-
trolled clinical trial conditions.
Clinical implications
The studies that have evaluated the dose–response rela-
tionship of SSRIs and SNRIs have been equivocal,with
considerable difficulties in establishing a clear optimal
dose or dose range in the treatment of major depression.
Clinicians who increase the dose of an SSRI in an early
nonresponder or partial responder, ie, before at least 
3 weeks at fixed dose, and then see improvement may
conclude that the subsequent response proved that the
patient needed a higher dose. However, it may be that
the patient simply needed a longer time on the drug to
achieve the response.This issue was confirmed by three
prospective studies on dose augmentation.
41-43This casts
doubt on the customary practice of increasing dosage
when there is nonresponse early in treatment,according
to dose-adjusted trial designs reported between 1980 and
2004.
The majority of depressed patients should be treated
with a low dosage of SSRIs and SNRI,generally corre-
sponding to one tablet per day.Increasing the dose may
perhaps be beneficial for some patients with depression,
in particular those with severe depression.An antide-
pressant for which this strategy may be relevant,in order
to increase the number of responders, is venlafaxine.
Although this has not been often studied, if higher
dosages are required, they will be better tolerated if
achieved through dose titration. ❏
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Relación dosis-respuesta de nuevos antide-
presivos en el tratamiento a corto plazo de
la depresión
Los fármacos antidepresivos están ampliamente
recomendados para el tratamiento de los trastor-
nos depresivos y un tema importante es el encon-
trar la “dosis adecuada para el paciente apro-
piado.” Independientemente del antidepresivo
prescrito, un porcentaje de pacientes adultos con
depresión mayor no responden satisfactoriamente
a un adecuado tratamiento de primera línea. Una
estrategia frecuente para pacientes con una res-
puesta insuficiente a una dosis inicial de antide-
presivos es aumentar la dosis. Esta revisión se
refiere a esta estrategia; es decir, los posibles bene-
ficios de prescribir dosis más altas de los nuevos
antidepresivos. De acuerdo con ensayos clínicos ran-
domizados, controlados y con dosis fijas los resul-
tados demuestran que una curva dosis-respuesta
aplanada es un fenómeno importante para los inhi-
bidores selectivos de la recaptación de serotonina
(ISRS). Para los inhibidores de la recaptación de
serotonina y noradrenalina (IRSN) la estrategia del
aumento de dosis puede ser relevante para la ven-
lafaxina, en cuanto a aumentar el número de res-
pondedores. De este modo, el subgrupo de pacien-
tes para los cuales las altas dosis de ISRS podrían ser
útiles aun está por definirse.       
Relation dose-réponse des antidépresseurs
récents dans le traitement à court terme de
la dépression
Les antidépresseurs sont largement recommandés
dans le traitement des troubles dépressifs et trou-
ver la « bonne dose pour le bon patient » est un
défi. Quel que soit l’antidépresseur prescrit, un cer-
tain nombre de patients adultes présentant une
dépression majeure ne répondent pas de façon
satisfaisante à un traitement initial. Une stratégie
fréquente pour les patients avec une réponse insuf-
fisante à un premier antidépresseur consiste à aug-
menter la dose. Cette revue concerne cette straté-
gie, c’est-à-dire les possibles bénéfices d’une
prescription de doses plus élevées pour les antidé-
presseurs récents. Les résultats montrent qu’une
courbe dose-réponse plate est un phénomène de
classe pour les inhibiteurs sélectifs du recaptage de
la sérotonine (ISRS), selon les études randomisées
et contrôlées, à doses fixes. Pour les antidépresseurs
inhibiteurs du recaptage de la sérotonine et de la
noradrénaline (IRSN), la stratégie d’augmenter la
dose peut être pertinente pour la venlafaxine, dans
le but d’accroître le nombre de répondeurs. Ainsi,
le sous-groupe de patients pour lesquels des doses
élevées d’ISRS pourraient s’avérer utiles reste à être
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